One of the fastest moving fields in today's biomedical research concerns small non-coding RNAs in general and microRNA (miRNA) in particular. As insights into the role of these RNA species in health and disease are emerging at high speed, so are the opportunities for developing new diagnostic, prognostic and therapeutic applications.

InteRNA Technologies focuses on these developments by translating its proprietary miRNA sequences and discovery technologies into successful clinical and commercial products.

InteRNA Technologies has currently apporximately 15% of the human miRNA sequences in its patent portfolio.